Nutra Pharma Corporation
791 Park Of Commerce Boulevard
Suite 300
Boca Raton,
FL 33487
United States - Map
Phone: 954-509-0911
Fax: 877-895-5647
Web Site: http://www.nutrapharma.com
| Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharmas wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The companys wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena. Nutra Pharma Corporation was founded in 2000 and is based in Boca Raton, Florida. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Rik J. Deitsch , 41
Chairman, Chief Exec. Officer, Pres and Chief Financial Officer |
$
130.00K | N/A | Dr. Paul F. Reid PhD., 45
Director, Co-Founder of ReceptoPharm Inc and Chief Exec. Officer of ReceptoPharm Inc |
N/A
| N/A | Mr. Neil Roth ,
Pres of Designer Diagnostics |
N/A
| N/A | Mr. Harold H. Rumph , 79
Director and Pres of ReceptoPharm Inc |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
3.07% Nasdaq 
0.004 (13.79%) 
Profile
